Angelini Ventures co-leads €20m Series A to advance RNA therapeutics for neurological disorders

Copenhagen-based biotech Neumirna Therapeutics has secured €20 million in a Series A funding round co-led by Angelini Ventures and Invivo Partners, with participation from Innovestor’s Life Science Fund and existing investors. The funding will advance Neumirna’s pioneering RNA therapeutics pipeline, including its lead candidate NMT.001, an antisense oligonucleotide (ASO) therapy targeting drug-resistant epilepsy.

Founded in 2020 by Dr. Henrik Klitgaard, Prof. Sakari Kauppinen, and Lars Hellerung Christiansen, Neumirna focuses on harnessing microRNAs (miRNAs) to develop therapies addressing the root causes of neurological disorders. The company’s innovative platform has enabled the development of RNA-based treatments for conditions like Parkinson’s disease and epilepsy, which have remained resistant to conventional therapies.

Angelini Ventures, marking its fifth investment in neuroscience, emphasised Neumirna’s potential to revolutionise treatment paradigms. By targeting “the underlying causes of diseases like epilepsy and Parkinson’s disease, Neumirna is breaking new ground in the field,” said Thomas Thestrup, longtime hunter for drug innovation and Senior Principal at Angelini Ventures.

This investment will fund clinical trials for NMT.001 and enhance Neumirna’s R&D capabilities. CEO Professor Janine Erler is excited: “This funding milestone is a testament to the groundbreaking potential of our RNA-based platform and our lead development candidate, NMT.001.”

With significant backing and a novel therapeutic approach, Neumirna aims to redefine treatment for patients with complex neurological conditions.